Galectin Therapeutics GALT 深 沪
等待开盘 09-23 09:30:00 美东时间
4.96
+0.160
+3.33%
华盛通- 最 高5.03
- 今 开4.91
- 成交量 7.50万股
- 最 低 4.8399
- 昨 收 4.80
- 总市值 3.18亿
- 52周最高 6.55
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.726
- 委 比 35.28%
- 总股本 6406.03万
- 历史最高 19.11
- 量 比 0.42
- 振 幅 3.96%
- 历史最低 0.49
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
Galectin Therapeutics Highlights Promising Belapectin Results
An update from Galectin Therapeutics ( ($GALT) ) is now available. On September...
09-08 20:21
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Galectin Therapeutics, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The company presentation will take place on September 8 at 1:00 PM ET and will be available via live and archived webcast. Galectin's management, including CEO Joel Lewis and CMO Khurram Jamil, M.D., will also be available for one-on-one meetings. The company is focused on developing therapi...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.
08-14 23:51
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from
08-14 20:09
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
**Galectin Therapeutics公司发布2025年上半年财务报告**：公司报告了截至2025年6月30日的三个月和六个月的财务结果和业务更新。Galectin Therapeutics的首席执行官Joel Lewis表示，NAVIGATE试验的持续数据分析进一步支持了Belapectin在MASH肝硬化患者中的临床效果。Belapectin在减少肝纤维化进展和食管静脉曲张方面的效果在超过18个月的治疗中仍然显著。公司相信这些发现表明Belapectin有潜力改变疾病进展。公司预期在2025年下半年公布更多生物标志物数据，并继续与美国FDA沟通。截至2025年6月30日，公司现金和现金等价物为1380万美元，并通过股东提供的额外1000万美元债务融资，支持运营至2026年下半年。第二季度研发费用为330万美元，较2024年同期下降。
08-14 12:00
Galectin Therapeutics Secures $10M Credit Line for Growth
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On July ...
07-09 20:16
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
<p>Galectin Therapeutics Inc. has secured a $10 million unsecured credit facility with its Chairman and largest shareholder, Richard E. Uihlein, to support its MASH cirrhosis program. The credit line, available until April 2026, carries an interest rate of 6.05% and includes convertible notes and stock purchase warrants. Uihlein highlighted his confidence in the Company's potential, while CEO Joel Lewis emphasized reduced shareholder dilution and...
07-09 12:00
【华鑫宏观策略】七月策略和十大金股
（转自：华鑫研究） ▌ 总量观点 海外关税暂缓周期结束，贸易风波或重启，但中美贸易冲突风险可控。同时中东停火后，全球风险偏好修复；联储降息预期升温...
07-01 09:00
Galectin, Comstock, Cooper, Nutrien, Monday: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($GALT) ), ( ($CRK) ), ( ($COO) ), ...
06-21 17:01
